99
RemeGen
9995.HK·HKEXYantai CNFounded 20081,500 employees
Mid CapbiotechPublicOncologyImmunology
Platform: ADC/Fusion
Market Cap
$2B
All Drugs
2
Clinical Trials
4
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (9995.HK)
Loading 9995.HK stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nirarapivir | 999-829 | Approved | 2 | GIP-R | MDDTTR Amyloidosis | ||
| Mavuinavolisib | 999-8225 | Phase 1 | 2 | IL-23 | Breast CaCKD |
SEC Filings & Financial Documents
SEC filings are not available for HKEX-listed companies.
RemeGen trades on HKEX (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (3)